Intraoperative Lidocaine Infusion as a Sole Analgesic Versus Morphine in Laparoscopic Gastric Bypass Surgery

Sponsor
Ain Shams University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05150756
Collaborator
(none)
60
1
2
8
7.5

Study Details

Study Description

Brief Summary

Postoperative opioid-centric pain management strategies in obese patients are accompanied by the possible development of; opioid-induced ventilatory impairment (OIVI) and hypoxemia. This presents as sedation and respiratory depression, combined with upper airway obstruction and hypercapnia. If it remains undetected and untreated, it can result in increased perioperative morbidity and mortality.Thus, an increased interest in the use of non-opioid analgesic adjuncts has been prompted.

Intra-operative intravenous lidocaine infusion has analgesic, anti-inflammatory, anti-hyperalgesic, opioid-sparing effects with an enhanced recovery after surgery (ERAS) profile. Its postoperative analgesia may last after reduction of its plasma concentration. So, lidocaine could be a good alternative in bariatric surgery.

Lidocaine has been studied as part of an opioid-free multimodal analgesia in morbidly obese patients. Also, its use in bariatric surgery showed a decrease in postoperative opioid use and improvement in the quality of recovery.

Condition or Disease Intervention/Treatment Phase
  • Drug: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
  • Drug: morphine sulphate (10mg/ ml ampoule)
Early Phase 1

Detailed Description

compare the postoperative analgesic effect of intraoperative lidocaine infusion (Study group) used as a sole analgesic agent, to the intraoperative intravenous morphine (Control group) in laparoscopic gastric bypass surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Intraoperative Lidocaine Infusion as a Sole Analgesic Versus Morphine in Laparoscopic Gastric Bypass Surgery
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group Lidocaine

At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.

Drug: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
Other Names:
  • Xylocaine 2%
  • Active Comparator: Group Morphine

    At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery

    Drug: morphine sulphate (10mg/ ml ampoule)
    At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery

    Outcome Measures

    Primary Outcome Measures

    1. Post-operative pain score at rest [1hour]

      Intensity of pain will be monitored ; on arrival to the PACU, at 20, 40 and 60 minutes after arrival to the PACU by the Numeric Pain Rating Scale. The Numeric Pain Rating Scale (NPRS) is a segmented numeric version of the visual analog scale (VAS) in which the patient selects a whole number (0-10 integers) that best reflects the intensity of pain felt.Where 0 is no pain felt and 10 is the worst pain.

    Secondary Outcome Measures

    1. Duration of surgery [3 hours]

      measured in minutes

    2. Duration of anesthesia [4 hours]

      measured in minutes

    3. mean values of mean blood pressure (MBP) [5 hours]

      mean values of MBP will be recorded as base line value, before induction of anesthesia, 5 minutes after endotracheal intubation, before pneumoperitoneum, after release of pneumoperitoneum and 10 min after extubation in the PACU

    4. Number of patients requiring intra-operative morphine [4hours]

      Number of patients requiring intra-operative morphine will be recorded

    5. sPO2 [5 hours]

      recorded in the induction room and in the PACU.

    6. Respiratory rate [5 hours]

      recorded in the induction room and in the PACU

    7. Post-operative nausea and/or vomiting [1 hour]

      number of patients will be recorded

    8. Post-operative sedation score [1 hour]

      From 0 to 4

    9. Modified Aldrete Score [1 hour]

      score from 0 to 10. Higher score means patient is fit to transfer to the ward. In the PACU, patients with score ≥ 9 will be transferred to the surgical unit

    10. mean values of heart rate (HR) [5 hours]

      mean values of HR will be recorded as base line value, before induction of anesthesia, 5 minutes after endotracheal intubation, before pneumoperitoneum, after release of pneumoperitoneum and 10 min after extubation in the PACU

    11. Number of patients requiring postoperative additional morphine doses [1 hour]

      Number of patients requiring postoperative additional morphine doses willbe recorded

    12. the total dose of morphine given to each patient [5 hours]

      the total dose of morphine given to each patient will be recorded in milligrams

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ASA physical status I- II

    • body mass index (BMI) ˃ 35

    • scheduled to undergo laparoscopic gastric bypass

    Exclusion Criteria:
    • Patients' refusal

    • hypersensitivity to the study medications

    • patients with known history of; hepatic disease, renal dysfunction

    • severe renal impairment (eGFR <30ml/min/1.73m2)

    • heart failure; left ventricular ejection fraction than 35%

    • any cardiac dysrhythmias; Adam-Stokes syndrome; Wolff- Parkinson-White syndrome, atrio-ventricular block with heart rate below 50 bpm

    • chronic pain

    • concomitantly taking beta blocking drugs •substance abuse disorder

    • chronic opioid use.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ain-Shams University Cairo Egypt

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ghada M.Samir, Assistant Professor of Anesthesia, Intensive care and Pain Management, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05150756
    Other Study ID Numbers:
    • R 35/ 2021
    First Posted:
    Dec 9, 2021
    Last Update Posted:
    Mar 22, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Ghada M.Samir, Assistant Professor of Anesthesia, Intensive care and Pain Management, Ain Shams University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 22, 2022